Efficacy and safety of canagliflozin (CANA) in patients with type 2 diabetes mellitus (T2DM) who progressed to stage 3A chronic kidney disease during treatment

被引：0

作者：

Roussel, R. ^{[1
]}

de Zeeuw, D. ^{[2
]}

Law, G. ^{[3
]}

Meininger, G. ^{[3
]}

机构：

[1] Hop Bichat Claude Bernard, F-75877 Paris, France

[2] Univ Groningen, NL-9700 AB Groningen, Netherlands

[3] Janssen Res & Dev LLC, Raritan, NJ USA

来源：

DIABETOLOGIA | 2014年 / 57卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

799

引用

页码：S322 / S323

页数：2

共 50 条

[1] Efficacy and Safety of Canagliflozin (CANA) in Subjects With Type 2 Diabetes Mellitus (T2DM) and Chronic Kidney Disease (CKD) Over 52 Weeks
Yale, Jean-Francois
Bakris, George
Cariou, Bertrand
Iglesias, Javier Nieto
Wajs, Ewa
Figueroa, Katherine
Jiang, Joel
Usiskin, Keith
Meininger, Gary
[J]. DIABETES, 2013, 62 : A277 - A278
[2] Efficacy and Safety of Canagliflozin (CANA) Monotherapy in Subjects With Type 2 Diabetes Mellitus (T2DM) Over 52 Weeks
Stenloef, Kaj
Cefalu, William T.
Kim, Kyoung-Ah
Jodar, Esteban
Alba, Maria
Edwards, Robert
Tong, Cindy
Canovatchel, William
Meininger, Gary
[J]. DIABETES, 2013, 62 : A303 - A303
[3] Achievement of Diabetes-related Treatment Goals with Canagliflozin (CANA) in Patients with Type 2 Diabetes Mellitus (T2DM)
Blonde, Lawrence
Woo, Vincent
Mathieu, Chantal
Yee, Jacqueline
Vijapurkar, Ujjwala
Meininger, Gary
[J]. DIABETES, 2014, 63 : A284 - A284
[4] Long-term Efficacy and Safety of Canagliflozin (CANA) in Older Patients with Type 2 Diabetes Mellitus (T2DM) Over 104 Weeks
Bode, Bruce
Stenlof, Kaj
Harris, Stewart
Sullivan, Daniel
Fung, Albert
Usiskin, Keith
[J]. DIABETES, 2014, 63 : A71 - A71
[5] Blood Pressure (BP) Effects of Canagliflozin (CANA) in Patients with Type 2 Diabetes Mellitus (T2DM)
Pfeifer, Michael
Townsend, Raymond
Davies, Michael J.
Vijapurkar, Ujjwala
Ren, Jimmy
[J]. DIABETES, 2016, 65 : A303 - A303
[6] Genital Mycotic Infections With Canagliflozin (CANA) in Subjects With Type 2 Diabetes Mellitus (T2DM)
Nyirjesy, Paul
Sobel, Jack
Fung, Albert
Gassmann-Mayer, Cristiana
Ways, Kirk
Usiskin, Keith
[J]. DIABETES, 2013, 62 : A276 - A276
[7] Effect of Canagliflozin (CANA) on Liver Function Tests (LFTs) in Patients with Type 2 Diabetes Mellitus (T2DM)
Usiskin, Keith
Leiter, Lawrence A.
Forst, Thomas
Polidori, David
Xie, John
Sha, Sue
[J]. DIABETES, 2014, 63 : A284 - A284
[8] Pharmacokinetics (PK) and Pharmacodynamics (PD) of Canagliflozin (CANA) in Pediatric Patients with Type 2 Diabetes Mellitus (T2DM)
Tamborlane, William
Polidori, David
Di Prospero, Nicolas
[J]. DIABETES, 2017, 66 : A371 - A371
[9] Efficacy and Safety of Canagliflozin (CANA) in Japanese Patients with Type 2 Diabetes Mellitus (T2DM) Inadequately Controlled with Diet and Exercise over 24 Weeks
Inagaki, Nobuya
Kondo, Kazuoki
Yoshinari, Toru
Maruyama, Nobuko
Takahashi, Nahoko
Susuta, Yutaka
Kuki, Hideki
[J]. DIABETES, 2014, 63 : A266 - A266
[10] Canagliflozin (CANA) Reduces Serum Uric Acid (SUA) in Patients with Type 2 Diabetes Mellitus (T2DM)
Davies, Michael
Trujillo, Angelina
Vijapurkar, Ujjwala
Damara-Ju, C. V.
Meininger, Gary
[J]. DIABETES, 2014, 63 : A283 - A284

← 1 2 3 4 5 →